CD274 and neoplasm: By binding to the PD-1 receptor on T-cells, PD-L1 suppresses their function, thereby promoting tumor survival and contributing to poor prognosis and resistance to conventional therapies in cancers such as melanoma, lung cancer, and OSCC [15].